Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17209435 | 1.00 | IRAK4 (1.00) | IRAK4 | |
| SCHEMBL30264362 | 1.00 | IRAK4 (1.00) | IRAK4 | |
| SCHEMBL30341835 | 1.00 | IRAK4 (1.00) | IRAK4 | |
| SCHEMBL17660855 | 0.96 | IRAK4 (1.00) | IRAK4 | |
| SCHEMBL19180894 | 0.96 | IRAK4 (1.00) | IRAK4 | |
| SCHEMBL19180811 | 0.91 | IRAK4 (1.00) | IRAK4 | |
| SCHEMBL19180810 | 0.91 | IRAK4 (1.00) | IRAK4 | |
| SCHEMBL19179620 | 0.90 | IRAK4 (1.00) | IRAK4 | |
| SCHEMBL17661482 | 0.90 | IRAK4 (1.00) | IRAK4 | |
| SCHEMBL19179621 | 0.90 | IRAK4 (1.00) | IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3200789-B1 | INHIBITORS OF IRAK4 ACTIVITY | MERCK SHARP & DOHME (US) | 2019-11-06 | — | — | EP | claimed |
| US-9932350-B2 | Inhibitors of IRAK4 activity | MERCK SHARP & DOHME CORP. (US) | 2018-04-03 | — | — | US | claimed |
| US-20170217981-A1 | INHIBITORS OF IRAK4 ACTIVITY | MERCK SHARP & DOHME CORP. (US) | 2017-08-03 | — | — | US | claimed |
| US-20250387393-A1 | ORAL COMPOSITIONS OF MK2 PATHWAY INHIBITOR FOR TREATMENT OF IMMUNE CONDITIONS | ACLARIS THERAPEUTICS, INC. (US) | 2025-12-25 | — | — | US | disclosed |
| US-12370195-B2 | Oral compositions of MK2 pathway inhibitor for treatment of immune conditions | ACLARIS THERAPEUTICS, INC. (US) | 2025-07-29 | — | — | US | disclosed |
| US-20240197732-A1 | ORAL COMPOSITIONS OF MK2 PATHWAY INHIBITOR FOR TREATMENT OF IMMUNE CONDITIONS | ACLARIS THERAPEUTICS, INC. | 2024-06-20 | — | — | US | disclosed |
| US-11844801-B2 | Oral compositions of MK2 pathway inhibitor for treatment of immune conditions | ACLARIS THERAPEUTICS, INC. (US) | 2023-12-19 | — | — | US | disclosed |
| EP-4132524-A1 | ORAL COMPOSITIONS OF MK2 PATHWAY INHIBITOR FOR TREATMENT OF IMMUNE CONDITIONS | Aclaris Therapeutics, Inc. (US) | 2023-02-15 | — | — | EP | disclosed |
| US-20210338669-A1 | ORAL COMPOSITIONS OF MK2 PATHWAY INHIBITOR FOR TREATMENT OF IMMUNE CONDITIONS | ACLARIS THERAPEUTICS, INC. | 2021-11-04 | — | — | US | disclosed |
| WO-2021195562-A1 | ORAL COMPOSITIONS OF MK2 PATHWAY INHIBITOR FOR TREATMENT OF IMMUNE CONDITIONS | ACLARIS THERAPEUTICS, INC. (US) | 2021-09-30 | — | — | WO | disclosed |
| EP-3200789-B1 | INHIBITORS OF IRAK4 ACTIVITY | MERCK SHARP & DOHME (US) | 2019-11-06 | — | — | EP | disclosed |
| US-9932350-B2 | Inhibitors of IRAK4 activity | MERCK SHARP & DOHME CORP. (US) | 2018-04-03 | — | — | US | disclosed |
| US-20170217981-A1 | INHIBITORS OF IRAK4 ACTIVITY | MERCK SHARP & DOHME CORP. (US) | 2017-08-03 | — | — | US | disclosed |
| US-20150329498-A1 | IRAK INHIBITORS AND USES THEREOF | NIMBUS IRIS, INC. | 2015-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250387393-A1 | ORAL COMPOSITIONS OF MK2 PATHWAY INHIBITOR FOR TREATMENT OF IMMUNE CONDITIONS | MAPKAPK2, MAP3K2, MAPK9 | IRAK4 220/4885 |
| US-11844801-B2 | Oral compositions of MK2 pathway inhibitor for treatment of immune conditions | RPS6KB2, MKNK2, DUSP2 | IRAK4 96/4885 |
| US-20240197732-A1 | ORAL COMPOSITIONS OF MK2 PATHWAY INHIBITOR FOR TREATMENT OF IMMUNE CONDITIONS | RPS6KB2, MKNK2, DUSP2 | IRAK4 96/4885 |
| US-20150329498-A1 | IRAK INHIBITORS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | IRAK4 4/4885 |
| US-12370195-B2 | Oral compositions of MK2 pathway inhibitor for treatment of immune conditions | RPS6KB2, MKNK2, DUSP2 | IRAK4 96/4885 |
| US-20170217981-A1 | INHIBITORS OF IRAK4 ACTIVITY | IRAK4, IRAK1, IRAK2 | IRAK4 1/4885 |
| US-20210338669-A1 | ORAL COMPOSITIONS OF MK2 PATHWAY INHIBITOR FOR TREATMENT OF IMMUNE CONDITIONS | RPS6KB2, MKNK2, DUSP2 | IRAK4 96/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.